Perkovic 2024 — FLOW Kidney CVOT Semaglutide

New England Journal of Medicine·May 24, 2024

Perkovic V, et al.

Summary

Semaglutide significantly reduced kidney disease progression and cardiovascular events in patients with T2D and CKD.

Study Details

Study Design

Phase 3 randomized, double-blind, placebo-controlled event-driven trial

Indication

CKD with T2D

Intervention

Semaglutide 1 mg weekly

Species

Human

Sample Size

3,533 subjects